Galapagos Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Galapagos han disminuido a una tasa media anual de -6.3%, mientras que en la industria Biotechs los beneficios crecieron en un 19.3% anualmente. Los ingresos han ido disminuyendo a una tasa media de 27.6% al año.

Información clave

-6.3%

Tasa de crecimiento de los beneficios

-9.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	-27.6%
Rentabilidad financiera	-2.1%
Margen neto	-23.3%
Próxima actualización de resultados	12 Feb 2025

Actualizaciones de resultados anteriores recientes

Recent updates

EMA panel approves amending label for Galapagos' Jyseleca on testicular function effects

Oct 03

Galapagos stock dips after Jefferies slashes rating citing challenges ahead

Jul 25

Galapagos: Can The Company Turn Around?

May 19

Galapagos: A History Of Disruptive Failures

Feb 22

Galapagos: The Investment Thesis Is More Appealing Than Ever

Dec 02

Galapagos, Gilead's Selection study on filgotinib in ulcerative colitis published in the Lancet

Jun 04

Galapagos reports Q1 results

May 06

Galapagos: Market Values Pipeline Below $0

Dec 30

Galapagos candidate shows positive action in IPF proof-of-concept study

Nov 30

Galapagos NV 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Galapagos Is A Buy Despite Setback In The U.S.

Oct 23

Desglose de ingresos y gastos

Cómo gana y gasta dinero Galapagos. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:GLPG Ingresos, gastos y beneficios (EUR Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Sep 24	260	-61	132	0
30 Jun 24	261	32	132	0
31 Mar 24	244	31	130	0
31 Dec 23	240	-4	126	0
30 Sep 23	544	-153	272	0
30 Jun 23	86	-46	63	-223
31 Mar 23	163	-69	103	0
31 Dec 22	241	-71	139	0
30 Sep 22	577	6	262	223
30 Jun 22	505	-81	230	223
31 Mar 22	507	-126	219	0
31 Dec 21	234	-121	132	0
30 Sep 21	474	-201	195	0
30 Jun 21	537	-219	202	0
31 Mar 21	488	-272	196	0
31 Dec 20	478	-311	185	0
30 Sep 20	455	-368	168	0
30 Jun 20	972	75	157	0
31 Mar 20	948	145	120	0
31 Dec 19	835	149	97	0
30 Sep 19	865	280	74	0
30 Jun 19	324	-66	52	0
31 Mar 19	314	-41	44	0
31 Dec 18	318	-29	40	0
30 Sep 18	255	-74	34	96
30 Jun 18	185	-126	30	96
31 Mar 18	161	-139	28	96
31 Dec 17	156	-116	27	0
30 Sep 17	193	-40	26	68
30 Jun 17	176	-27	26	68
31 Mar 17	177	4	25	68
31 Dec 16	152	54	24	68
30 Sep 16	78	-49	23	49
30 Jun 16	72	-52	22	49
31 Mar 16	55	-68	21	49
31 Dec 15	61	-118	20	49
30 Sep 15	75	-72	18	35
30 Jun 15	82	-57	17	35
31 Mar 15	88	-44	15	35
31 Dec 14	90	-37	15	35
30 Sep 14	86	-32	14	6
30 Jun 14	92	-25	14	13
31 Mar 14	94	-21	14	20
31 Dec 13	97	-17	14	27

Ingresos de calidad: GLPG actualmente no es rentable.

Margen de beneficios creciente: GLPG actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: GLPG no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 6.3% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de GLPG en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: GLPG no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (16.6%).

Rentabilidad financiera

Alta ROE: GLPG tiene una rentabilidad financiera negativa (-2.12%), ya que actualmente no es rentable.

Galapagos Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Galapagos NV to Report First Half, 2025 Results on Jul 23, 2025

Galapagos NV to Report Fiscal Year 2024 Results on Feb 12, 2025

Galapagos NV to Report First Half, 2024 Results on Aug 01, 2024

Galapagos NV to Report Q4, 2023 Results on Mar 28, 2024

Galapagos NV to Report Fiscal Year 2022 Final Results on Mar 23, 2023

Galapagos NV to Report Q1, 2023 Results on May 04, 2023

Recent updates

Galapagos NV to Report First Half, 2025 Results on Jul 23, 2025

Galapagos NV Announces Board Changes

Galapagos Announces FDA Clearance of IND Application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in Relapsed/Refractory Non-Hodgkin Lymphoma

Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond

Galapagos NV to Report Fiscal Year 2024 Results on Feb 12, 2025

Galapagos NV Announces Board Changes

Galapagos: Pipeline Still Progressing Despite Financial Volatility

Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024

Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV (ENXTAM:GLPG).

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-Of-Care Manufactured BCMA CAR-T Candidate, GLPG5301

Galapagos Presents New Encouraging Clinical Data from the Ongoing Phase 1/2 CD19 CAR-T Studies with GLPG5201 and GLPG5101

Galapagos NV to Report First Half, 2024 Results on Aug 01, 2024

Galapagos NV Announces Board Changes

Galapagos NV to Report Q4, 2023 Results on Mar 28, 2024

Galapagos NV Announces Start of Phase 2 Study with Selective Tyk2 Inhibitor, GLPG3667, in Patients with Active Systemic Lupus Erythematosus

Galapagos NV Revises Sales Guidance for the Full Year 2023

Galapagos Appoints Thad Huston as Chief Financial Officer, Effective from July 1, 2023

Galapagos NV Announces Director Changes

Galapagos to Showcase CAR-T Point-Of-Care Manufacturing and Initial Phase 1/2 CLL Data with CD19 CAR-T Candidate, GLPG5201, at the EHA 2023 Congress

Galapagos NV Announces Topline Results from Phase 3 DIVERSITY Trial of Filgotinib in Crohn’s Disease

Galapagos NV Announces Changes in the Executive Committee Effective 1 January 2023

Galapagos and CellPoint Presented Encouraging Initial Data AtASH 2022 for GLPG5101, a CD19 CAR-T Candidate Manufactured At Point-Of-Care

Galapagos Announces CHMP Adoption of PRAC’s Recommendation for Jyseleca® Following Extensive Safety Review of all JAK Inhibitors

Galapagos NV to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Galapagos NV to Report Fiscal Year 2022 Final Results on Mar 23, 2023

Galapagos NV to Report Q1, 2023 Results on May 04, 2023

Galapagos: Trading At Discount To Cash With A Fast-Growing Marketed Product

Galapagos Receives Positive CHMP Opinion for Jyseleca® European Label Update Based on Testicular Function Safety Data from MANTA/RAy Studies

EMA panel approves amending label for Galapagos' Jyseleca on testicular function effects

Galapagos NV announced that it has received €3.07625 million in funding

Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022

Galapagos stock dips after Jefferies slashes rating citing challenges ahead

Galapagos NV (ENXTAM:GLPG) entered into a definitive agreement to acquire Abound Bio, Inc. for $14 million.

Galapagos NV announced that it expects to receive €1.459507 million in funding

Galapagos: Can The Company Turn Around?

Galapagos NV to Report Q3, 2022 Results on Nov 03, 2022

Galapagos NV Announces Executive Appointments

Galapagos NV Announces Approval of Additional Indication Based on Phase 2B/3 SELECTION Study in Patients with Moderate-To-Severe Ulcerative Colitis

Galapagos: A History Of Disruptive Failures

Galapagos Provides Further Insights into the Treatment of Ulcerative Colitis At the European Crohn’s and Colitis Organization Annual Congress

Galapagos NV Announces Authorization of Medicines and Healthcare Products Regulatory Agency for Jyseleca (Filgotinib), as New Treatment for Ulcerative Colitis in Great Britain

Galapagos: The Investment Thesis Is More Appealing Than Ever

Galapagos Nv Completes Patient Recruitment for Mangrove Phase 2 Trial with GLPG2737 in Polycystic Kidney Disease

Galapagos Announces Positive CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Galapagos NV Demonstrates Early Clinical Activity with SIK2/3 Inhibition in Inflammation

Galapagos NV Announces That Primary and Secondary Endpoint Results from the Phase 3 SELECTIONinduction

Galapagos, Gilead's Selection study on filgotinib in ulcerative colitis published in the Lancet

Galapagos NV to Present Data on Rheumatoid Arthritis At the Upcoming European League Against Rheumatism (EULAR) Congress

Galapagos Announces First Patient Enrolled in FILOSOPHY Study to Advance Understanding of Jyseleca (Filgotinib) Effectiveness and Safety in A Real-World Setting

Galapagos reports Q1 results

Galapagos Reports Primary Endpoint for the Ongoing Filgotinib MANTA and MANTA-RAy Safety Studies

Galapagos NV to Report Fiscal Year 2020 Final Results on Mar 25, 2021

Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF

Galapagos NV to Report Fiscal Year 2021 Results on Feb 24, 2022

NICE Recommends Galapagos Jyseleca (Filgotinib) on NHS in Decision for Rheumatoid Arthritis

Selvita S.A. (WSE:SLV) completed the acquisition of Fidelta D.O.O. from Galapagos NV (ENXTAM:GLPG).

Galapagos: Market Values Pipeline Below $0

Gilead Sciences, Inc. and Galapagos NV Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)

Galapagos NV Reports Positive Topline Results with GLPG1205 in IPF Patients in PINTA Proof-of-Concept Trial

Galapagos NV Announces First Dosing in MANGROVE Phase 2 Trial with GLPG2737 in Polycystic Kidney Disease

Galapagos candidate shows positive action in IPF proof-of-concept study

Selvita S.A. (WSE:SLV) signed an agreement to acquire 100% stake in Fidelta D.O.O. from Galapagos NV (ENXTAM:GLPG) for an enterprise value of €31.2 million.

Galapagos NV Announces Dosing of the First Psoriasis Patient in the Phase 1B Trial with GLPG3667

Galapagos NV 2020 Q3 - Results - Earnings Call Presentation

Gilead Sciences, Inc. and Galapagos NV Announce the Application for A New Indication to the Approved License

Galapagos NV Unveils the Toledo Target Family as a Series of Salt-Inducible Kinase Inhibitors

Galapagos Is A Buy Despite Setback In The U.S.

Galapagos and Servier Report Topline Results for Roccella Phase 2 Clinical Trial with Glpg1972/S201086 in Knee Osteoarthritis Patients